HER2-Low Breast Carcinoma — Trials

HER2-Low Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 12
Ph III recruiting: 1
Growth YoY: —
Industry share: 14%
Top sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07796880	Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer	recruiting	Phase 2	80	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Sep 15, 2026	clinicaltrials
NCT06298084	Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd(ICARUSBREAST02)	recruiting	Phase 1 / Phase 2	152	Gustave Roussy, Cancer Campus, Grand Paris